Case Report

Extraosseous Multiple Myeloma: Case Report of Presentation in the Lower Extremity Soft Tissues with Literature Review

Jeff Ames,1 Ahmad Al-Samaraee,1 and Takashi Takahashi2

1Department of Radiology, University of Minnesota, Minneapolis, MN, USA
2Musculoskeletal Division, Department of Radiology, University of Minnesota, Minneapolis, MN, USA

Correspondence should be addressed to Takashi Takahashi; takas005@umn.edu

Received 20 August 2017; Revised 7 November 2017; Accepted 20 November 2017; Published 17 December 2017

1. Introduction

Solitary plasmacytomas and multiple myeloma can be thought of as a spectrum of disease, which ranges from localized clonal plasma cell infiltration to multiple extramedullary lesions, and osseous forms typically progress to multiple myeloma. Multiple myeloma is the most common primary osseous malignancy in adults, typically between the ages of 50 and 70, and it is more likely to affect men [1]. Multiple myeloma is defined by >10% of clonal plasma cells in bone marrow or biopsy-proven extramedullary plasmacytoma and by the evidence of end-organ damage including bone lesions and renal insufficiency [2].

The importance of diagnosing patients with atypical presentations cannot be understated as approximately 10–20% of multiple myeloma patients do not present with lytic lesions on radiography [3], and as a result MRI and PET/CT have become increasingly important in the diagnosis of multiple myeloma. It is also important to note that incidence of extramedullary myeloma is found to be 6–8% of newly diagnosed multiple myeloma patients [2]. The prevalence increases to 10–30% in relapsed/refractory patients. The disease remains incurable; however improving diagnosis and therapies have led to increasing length of survival, which has in turn increased the prevalence of atypical disease progression or features of relapse, such as extramedullary lesions [4].

2. Case Presentation

The patient was a previously healthy 51-year-old man who presented to the Emergency Department with back pain which he initially believed to be a pulled muscle but did not improve after three weeks. He was given pain medications, and he later followed up with his primary care physician, who ordered an MRI of his thoracic spine. The thoracic spine MRI showed diffuse marrow abnormality involving the entire thoracic spine, including anterior and posterior elements as well as visualized portions of the ribs. There was also epidural extension of the tumor at T5 level resulting in relatively severe central stenosis and displacement of the thoracic cord. Baseline imaging consisted of a bone survey which demonstrated numerous myelomatous lesions throughout the axial and appendicular skeleton.

Laboratory studies at that time demonstrated hypercalcemia and elevated creatinine, concerning for myeloma. He was started on a course of steroids with Velcade and Revlimid,
and involved field radiation therapy to the thoracic spine was started with a total dose of 3000 cGy given in 10 fractions. Serum protein electrophoresis demonstrated an M-spike of 0.8 g/dL within IgG lambda. Bence Jones proteinuria was present in the range of 2 g. Biopsy of his bone marrow was consistent with aggressive myeloma with elevated plasma cells (18%), and a thorough cytogenetic evaluation demonstrated multiple abnormalities, including monosomy 13, t(4;14), deletion of 17p and 13q, and gain of 1q21. The patient was stage III (both ISS and R-ISS). He was seen shortly after diagnosis for evaluation of stem cell transplantation, and, given such a high risk of his underlying myeloma, the patient was recommended to consider allogeneic stem cell transplantation from an alternative donor source. He was also evaluated for a second opinion at an outside institution, which also recommended allogeneic stem cell transplantation in the first complete remission.

The patient completed induction therapy with VRD and achieved complete response. He underwent fludarabine-cyclophosphamide-antithymocyte antoglobulin preparation prior to a single cord blood allogeneic transplant. A repeat bone marrow biopsy following transplant did not show any evidence of multiple myeloma, and there was 91% donor chimerism. Immunosuppression leads to numerous episodes of pneumonia, and his course was complicated by renal insufficiency and acute grade III graft versus host disease, which was successfully treated with a steroid taper.

The patient was admitted approximately 5 months after transplantation for bilateral lower extremity swelling, multiple deep venous thrombi, and concern for bilateral thigh swelling. The thigh swelling was initially evaluated with ultrasound, which was read as possibly representative of hematoma in the setting of anticoagulation (Figure 1(a)). An MRI was obtained of the patient's thighs, which demonstrated extensive soft tissue enhancement bilaterally concerning for extraosseous multiple myeloma rather than hematoma (Figure 2). These soft tissue masses were biopsy-proven extraosseous plasmacytomas. Overall, the bone marrow biopsy findings were most consistent with recurrent/residual low-level multiple myeloma. Finally, a PET/CT revealed extensive osseous lesions, pulmonary involvement with pleural effusion, and numerous intramuscular lesions (Figure 3). His relapse was initially managed with VD-PACE. The patient's renal disease progressed rapidly in the following months, which ultimately led to his death despite salvage therapy (Thal/Dex/Velcade/Doxil).

3. Discussion

To further understand the relative proportion of anatomic locations of solitary plasmacytomas and multiple myeloma lesions outside of osseous structures, a literature review was conducted to capture all published extraosseous lesions. Many clinicians use the term “extramedullary,” which complicated the search as this could potentially be used for osseous lesions outside of bone marrow. All articles were assessed to ensure lesions were nonosseous. Lesions contiguous with or arising from osseous structures were not included [2, 5]. Plasma cell leukemias were not included [2]. Extramedullary disease was assumed not to arise from bone

Figure 1: Gray scale images in transverse (a, c), longitudinal (d), and color Doppler (b) of the distal right thigh of a 51-year-old male with bilateral lower extremities pain and swelling. Images demonstrate area of heterogeneous echogenicity with internal flow in the distal right thigh. Initial interpretation was that the findings might represent muscular hematoma with possible active bleeding from overanticoagulation.
when not explicitly stated. Most articles did not distinguish between extramedullary disease found at diagnosis and relapse.

Multifocal extramedullary disease is possible, but unless explicitly stated only the site of interest in the publication was included. PubMed was searched for "(Extraosseous OR Extramedullary) Multiple Myeloma," and the following filters were applied: Humans, English, and All adult (19+ years old). Since 1966, there have been 713 articles published, 318 of which were excluded in the literature search as the articles were not relevant or did not specify location of extramedullary disease or access was prevented by a pay-wall (Figure 4). The included 395 articles described 2,027 patients with extramedullary disease and described 2,538 lesions (Figure 5). The majority of extramedullary lesions were in the upper airway (34%), soft tissues (14%), gastrointestinal tract (10%), or central nervous system/head and neck (16%) (Tables 1 and 2). We were able to find only 44 documented cases of extremity soft tissue lesions, comprising 2% of all lesions.

Our analysis includes all published cases of extramedullary disease, and as a result will suffer from publication bias. The anatomic distribution of extramedullary disease in the current literature review is discordant in some ways with previous retrospective/prospective analyses, for example, Usmani et al. [6]. Usmani et al. found extramedullary lesions most commonly in the abdomen/pelvis, skin/soft tissues, and paraspinal regions. We found lesions most commonly in the upper airway and oral cavity, with the central nervous system/head and neck the second most common location. The differences in anatomic distribution may be due to a larger sample size or publication bias or may represent a real change in the distribution over the past 50 years in the setting of changing therapies. Another important confounding factor is how lesions are grouped together. One feature of our analysis that was consistent with previous studies was the finding that extramedullary disease in the extremities was extremely uncommon.

Diagnosis of extramedullary disease is uncommon yet clinically important because it is associated with shorter progression-free and overall survival. The presence of extramedullary disease is also correlated with genomically high risk disease and increased rates of relapse [6]. It is also
Figure 3: PET CT of the same 51-year-old male after approximately one week from the earlier shown US. ((a) and (c)) are coronal images of the whole body (a) and thighs (c) showing multiple foci of increased FDG uptake. (b) is an axial image of the distal thighs showing multiple foci of increased FDG uptake; the largest lesion on the posterior right thigh has SUV max of 4.3. (d) is a sagittal view of the same lesion showing its craniocaudal extension. Lesions were initially presumed and later biopsy proven to represent extra-axial multiple myeloma.

Table 1: Extraosseous myeloma distribution.

| Site                              | Lesions | %   |
|-----------------------------------|---------|-----|
| Upper airways, sinuses, and oral cavity | 858     | 33.8|
| Central nervous system, head and neck | 405     | 16.0|
| Soft tissue (not extremities)     | 357     | 14.1|
| Gastrointestinal                  | 262     | 10.3|
| Thoracic                          | 192     | 7.6 |
| Reticuloendothelial system        | 164     | 6.5 |
| Skin (not extremities)            | 154     | 6.1 |
| Genitourinary                     | 60      | 2.4 |
| Extremities                       | 44      | 1.7 |
| Not otherwise specified           | 42      | 1.7 |
| Total                             | 2538    | 100.0|
Table 2: Comprehensive table of extraosseous myeloma lesion distributions.

| Extremities           |   |
|-----------------------|---|
| Arm (skin)            | 1 |
| Buttocks (SQ)         | 1 |
| Fingers               | 2 |
| Forearm               | 2 |
| Gastrocnemius         | 1 |
| Gluteus maximus       | 2 |
| Knee                  | 1 |
| Knee (SQ)             | 1 |
| Leg (skin)            | 1 |
| Leg (soft tissue)     | 4 |
| Leg (SQ)              | 1 |
| Lower extremity       | 6 |
| Median nerve          | 1 |
| Shoulder girdle       | 2 |
| Sural nerve           | 1 |
| Thigh                 | 7 |
| Thigh (skin)          | 1 |
| Thigh (SQ)            | 1 |
| Toes                  | 1 |
| Triceps (SQ)          | 1 |
| Upper extremity       | 6 |

| Gastrointestinal      |   |
|-----------------------|---|
| Colon                 | 11|
| Duodenum              | 9 |
| Esophagus             | 1 |
| Gallbladder           | 1 |
| “GI tract NOS”        | 45|
| “Intra-abdominal lesions” | 8|
| Jejunum               | 2 |
| Liver                 | 67|
| Mesentery             | 6 |
| Omentum               | 3 |
| Pancreas              | 31|
| Pelvic mass           | 7 |
| Peritoneum            | 31|
| Rectum                | 3 |
| “Small bowel NOS”     | 8 |
| Stomach               | 29|

| GU                    |   |
|-----------------------|---|
| Bladder               | 5 |
| Kidney                | 26|
| Lower urinary tract   | 1 |
| Ovary                 | 6 |
| Penis                 | 1 |
| Prostate              | 1 |
| Scrotum               | 1 |
| Testicle              | 13|
| Uterus                | 1 |
| Location                              | Count |
|---------------------------------------|-------|
| Vagina                                | 3     |
| Vulva                                 | 2     |
| **CNS, head and neck**                | 405   |
| Ears                                  | 1     |
| “Eye or brain”                        | 41    |
| “Head and Neck NOS”                   | 64    |
| “Intracranial or Head/neck NOS”       | 6     |
| Middle ear                            | 2     |
| Parapharyngeal space                  | 3     |
| Parotid gland                         | 15    |
| Preauricular region                   | 1     |
| Pterygoid fossa                       | 1     |
| Submandibular gland                   | 3     |
| “Submaxillary gland”                  | 1     |
| Supraclavicular fossa                 | 4     |
| Thyroid                               | 23    |
| Conjunctiva                           | 3     |
| Eyelid                                | 5     |
| Lacrimal gland                        | 2     |
| Orbit                                 | 19    |
| CNS                                   | 196   |
| Retrobulbar                           | 15    |
| **RES**                               | 164   |
| Lymph node                            | 141   |
| Spleen                                | 23    |
| **Skin**                              | 154   |
| Abdomen                               | 1     |
| Cheek                                 | 6     |
| Cutaneous NOS                         | 130   |
| Nose                                  | 1     |
| Scalp                                 | 10    |
| Sternum                               | 3     |
| Within scars                          | 3     |
| **Soft tissue**                       | 357   |
| “Muscle NOS”                          | 5     |
| “Old catheter sites”                  | 1     |
| “Soft tissue NOS”                     | 123   |
| “Surrounding axial skeleton”          | 105   |
| Abdomen                               | 13    |
| Adrenal                               | 9     |
| Axilla                                | 2     |
| Bone marrow biopsy site               | 1     |
| Breast                                | 28    |
| Groin                                 | 1     |
| Hips                                  | 1     |
| Iliopsoas                             | 5     |
| Infratemporal fossa                   | 1     |
| Inguinal                              | 2     |
| Neck                                  | 9     |
| Location                                | Count |
|-----------------------------------------|-------|
| Paravertebral                           | 11    |
| Periadrenal fat                         | 1     |
| Perirenal                               | 5     |
| Presacral                               | 1     |
| Retroperitoneum                         | 23    |
| Subcutaneous NOS                         | 8     |
| Trunk                                   | 2     |
| **Thoracic**                            | **192**|
| Aorta                                   | 1     |
| Chest/thoracic wall                     | 45    |
| Diaphragm                               | 1     |
| Heart                                   | 5     |
| Lung                                    | 65    |
| Mediastinum                             | 18    |
| Pericardium                             | 6     |
| Pleura + pleural effusion               | 51    |
| **Other NOS**                           | **42**|
| **Upper airway**                        | **858**|
| Tongue                                  | 13    |
| Cricoid                                 | 2     |
| Epiglottis                              | 3     |
| Ethmoid sinus                           | 16    |
| False vocal cord                        | 1     |
| Gingiva/gums                            | 24    |
| Larynx                                  | 47    |
| Lips                                    | 1     |
| Maxillary sinus + maxilla + antrum      | 61    |
| “Mouth/pharynx NOS”                     | 115   |
| Nares                                   | 5     |
| Nasal cavity/fossa/mucosa               | 56    |
| Nasal polyp                             | 1     |
| Nasal septum                            | 6     |
| Nasooropharynx                          | 2     |
| Nasopharynx                             | 103   |
| Nose                                    | 39    |
| Oropharynx                              | 25    |
| “Palate/gum/maxilla NOS”                | 11    |
| Paranasal sinus + sinus                 | 37    |
| Pharynx                                 | 19    |
| “Respiratory NOS”                       | 133   |
| Rhinopharynx                            | 4     |
| Sinonasal/nasal sinus                   | 41    |
| Soft palate + palate + hard palate      | 4     |
| Sphenoid sinus                          | 15    |
| Subglottic                              | 5     |
| Supraglottic                            | 2     |
| Thyroid cartilage                       | 7     |
| Tonsil                                  | 49    |
| Trachea                                 | 3     |
| Vocal cords                             | 4     |
| “Upper respiratory tract NOS”           | 4     |
important to note that extramedullary disease can demonstrate a different genomic profile as compared to plasma cells in the bone marrow of the same patient [7]. Traditional radiography classically demonstrates osseous myeloma as lytic lesions without sclerotic margins; however these lesions are not radiographically apparent in a minority of cases which can lead to false negatives. As patients undergo repeated cycles of therapy, tumor serum markers and cross-sectional imaging are both used to determine therapy response.

Conventional radiography or bone survey has traditionally been the most common imaging modality in multiple myeloma; however there are numerous and increasing reasons why radiography alone is no longer adequate. Extramedullary nonosseous disease will not be visualized radiographically and as myeloma patients are living longer, extramedullary disease becomes more common and subsequently cross-sectional radiological evaluation should be considered, including MRI or PET/CT. Additionally, a systematic review performed by Regelink et al. in 2013 demonstrated greater sensitivity for osseous lesions with cross-sectional imaging when compared to radiography and supported the guidelines of the International Myeloma Working Group which state that whole body CT may replace bone survey [8, 9]. Conventional radiography also lacks the functional information that can be provided by PET/CT, which is now recommended as the preferred method of monitoring therapy response given its ability to differentiate metabolically active from inactive disease [10]. PET/CT and MRI detect bone damage earlier than bone survey, and posttreatment metabolic activity on PET/CT is an important prognostic factor. Comparison of baseline versus posttreatment PET/CT metabolic activity is increasingly important in the setting of novel highly active agents, as it allows for identification of patients with minimal residual disease negativity.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Jeff Ames analyzed data and wrote the manuscript. Ahmad Al-Samaraee analyzed data and Takashi Takahashi designed the study and edited the manuscript.

References

[1] C. J. Hanrahan, C. R. Christensen, and J. R. Crim, “Current concepts in the evaluation of multiple Myeloma with MR imaging and FDG PET/CT,” *Radiographics*, vol. 30, no. 1, pp. 127–142, 2010.
[2] C. Touzeau and P. Moreau, “How i treat extramedullary myeloma,” Blood, vol. 127, no. 8, pp. 971–976, 2016.

[3] R. Ferraro, A. Agarwal, E. L. Martin-Macintosh, P. J. Peller, and R. M. Subramaniam, “MR imaging and PET/CT in diagnosis and management of multiple myeloma,” Radiographics, vol. 35, no. 2, pp. 438–454, 2015.

[4] S. K. Kumar, S. V. Rajkumar, A. Dispenzieri et al., “Improved survival in multiple myeloma and the impact of novel therapies,” Blood, vol. 111, no. 5, pp. 2516–2520, 2008.

[5] M. Weinstock and I. M. Ghobrial, “Extramedullary multiple myeloma,” Leukemia & Lymphoma, vol. 54, no. 6, pp. 1135–1141, 2013.

[6] S. Z. Usmani, C. Heuck, A. Mitchell et al., “Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents,” Haematologica, vol. 97, no. 11, pp. 1761–1767, 2012.

[7] L. Rasche, S. S. Chavan, O. W. Stephens et al., “Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing,” Nature Communications, vol. 8, no. 1, 2017.

[8] J. C. Regelink, M. C. Minnema, E. Terpos et al., “Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review,” British Journal of Haematology, vol. 162, no. 1, pp. 50–61, 2013.

[9] S. V. Rajkumar, M. A. Dimopoulos, and A. Palumbo, “International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma,” The Lancet Oncology, vol. 15, no. 12, pp. e538–e548, 2014.

[10] M. Cavo, E. Terpos, C. Nanni et al., “Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group,” The Lancet Oncology, vol. 18, no. 4, pp. e206–e217, 2017.